MODHEP
Systems biology of liver cancer: an integrative genomic-epigenomic approach
| Coordinatore | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Organization address
address: VIA MOREGO 30 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 16˙861˙941 € |
| EC contributo | 11˙936˙899 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2016-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Organization address
address: VIA MOREGO 30 contact info |
IT (GENOVA) | coordinator | 687˙841.70 |
| 2 |
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Organization address
address: Via Filodrammatici 10 contact info |
IT (MILANO) | participant | 1˙762˙573.32 |
| 3 |
INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
FR (PARIS) | participant | 1˙362˙500.00 |
| 4 |
RIKEN THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH
Organization address
address: HIROSAWA 2-1 contact info |
JP (WAKO SHI SAITAMA) | participant | 951˙000.00 |
| 5 |
FONDAZIONE TELETHON
Organization address
address: VIA VARESE 16/B contact info |
IT (ROMA) | participant | 825˙230.99 |
| 6 |
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
Organization address
address: KLOVENIERSBURGWAL 29 HET TRIPPENHUIS contact info |
NL (AMSTERDAM) | participant | 805˙000.00 |
| 7 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 800˙000.00 |
| 8 |
THE BABRAHAM INSTITUTE
Organization address
address: Babraham Hall contact info |
UK (CAMBRIDGE) | participant | 797˙486.00 |
| 9 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 760˙004.00 |
| 10 |
WEIZMANN INSTITUTE OF SCIENCE
Organization address
address: HERZL STREET 234 contact info |
IL (REHOVOT) | participant | 647˙999.00 |
| 11 |
MATER MEDICAL RESEARCH INSTITUTE LIMITED
Organization address
address: LEVEL 3 AUBIGNY PLACE contact info |
AU (SOUTH BRISBANE) | participant | 577˙570.00 |
| 12 |
FONDAZIONE SANTA LUCIA
Organization address
address: VIA ARDEATINA 306 contact info |
IT (Roma) | participant | 574˙148.00 |
| 13 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 493˙177.00 |
| 14 |
BIOBYTE SOLUTIONS GMBH
Organization address
address: Bothestrasse 142 contact info |
DE (Heidelberg) | participant | 318˙600.00 |
| 15 |
ACIES Consulting Group SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 295˙569.99 |
| 16 |
NOVAMEN SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 167˙210.01 |
| 17 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 99˙085.00 |
| 18 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 11˙903.99 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cancer is a complex disease involving multiple genetic and epigenetic events occurring, and influencing each other, over a long period of time. Understanding cancer, and ultimately developing effective targeted therapies, will therefore require that mutations and epigenetic alterations be systematically investigated during the multiple stages of disease development, from identifiable pre-neoplastic phases to overt cancer. Until now, no systematic effort has been undertaken to investigate these multiple layers of genome organization and function during cancer development. MODHEP aims at providing a 360° understanding of liver cancer, one of the most common types of tumors and, because of the homogeneity of the hepatic tissue, the most experimentally tractable one. The consortium brings together elite European scientists in the fields of genetics, chromatin regulation, genomics, liver cancer, computational and systems biology. This combination of skills will allow us to investigate and model at unprecedented resolution the chain of events leading from environmental perturbations and the occurrence of driver mutations to preneoplastic disease and cancer. Our experimental plan reflects some grounded assumptions: 1. cancer cannot be modeled without detailed information on the preneoplastic stages of disease; 2. genetic heterogeneity in humans would make systems-level modeling non realistic from a practical point of view. Both of these limitations are bypassed by the use of well-defined mouse models, followed by evaluation of the main conclusions in clinical samples; 3. many early stage driving events in cancer represent epigenetic alterations, which are invisible to classical genetic analysis, and are confounded by secondary and tertiary events in established tumors. Our approach will enable the identification of therapeutically relevant early-stage genetic and epigenetic alterations and the definition of their interplay in tumor development and maintenance.'
Introduzione (Teaser)
Cancer is a complex disease involving multiple genetic and epigenetic events in different stages. An EU-funded project is studying the onset and development of liver cancer for facilitating effective anti-cancer therapy.